Skip to main content

Table 1 Treatment effects within subgroups defined by primary tumor location in patients with RAS wild-type metastatic colorectal cancer

From: Should anti-EGFR mAbs be discontinued for conversion surgery in untreated right-sided metastatic colorectal cancer? A systematic review and meta-analysis

Study Intervention Number of response Number of patients ORR (%) OR 95% CI P value
Right-sided colorectal cancer
 PRIME [20] FOLFOX + panitumumab
FOLFOX
16
16
38
46
42.1
34.8
1.364 0.56–3.30 0.492
 TAILOR [21] FOLFOX + cetuximab
FOLFOX
20
9
45
38
44.4
23.7
2.578 0.99–6.67 0.051
 CRYSTAL [22] FOLFIRI + cetuximab
FOLFIRI
1417 3351 42.4
33.3
1.474 0.60–3.64 0.4
 MACRO-2/PLANET [25] FOLFIRI/FOLFOX + panitumumab 11 33 33.3
 VOLFI [23] FOLFOXIRI + panitumumab
FOLFOXIRI
6
3
10
8
60
37.5
2.500 0.37–16.88 0.347
 PEAK [20] FOLFOX + panitumumab
FOLFOX + bevacizumab
14
7
22
14
63.6
50.0
1.75 0.45–6.83 0.42
 FIRE-3 [24] FOLFIRI + cetuximab
FOLFIRI + bevacizumab
18
19
30
38
60.0
50.0
1.500 0.57–3.95 0.412
 CALGB80405 [13] FOLFIRI/FOLFOX + cetuximab
FOLFIRI/FOLFOX + bevacizumb
30
31
71
78
42.3
39.7
1.109 0.58–2.13 0.756
Left-sided colorectal cancer
 PRIME [20] FOLFOX + panitumumab
FOLFOX
114
82
168
156
67.9
52.6
1.905 1.21–2.99 0.005
 TAILOR [21] FOLFOX + cetuximab
FOLFOX
97
70
146
162
66.4
43.2
2.602 1.63–4.13 < 0.001
 CRYSTAL [22] FOLFIRI + cetuximab
FOLFIRI
103
56
142
138
72.5
40.6
3.867 2.34–6.38 < 0.001
 MACRO-2/PLANET [25] FOLFIRI/FOLFOX + panitumumab 78 148 52.7
 VOLFI [23] FOLFOXIRI + panitumumab
FOLFOXIRI
48
17
53
25
90.6
68
4.518 1.30–15.72 0.018
 PEAK [20] FOLFOX + panitumumab
FOLFOX + bevacizumab
34
31
53
54
64.1
57.4
1.328 0.61–2.89 0.476
 FIRE-3 [24] FOLFIRI + cetuximab
FOLFIRI + bevacizumab
93
78
124
133
75.0
58.6
2.115 1.24–3.60 0.006
 CALGB80405 [13] FOLFIRI/FOLFOX + cetuximab
FOLFIRI/FOLFOX + bevacizumb
120
88
173
152
69.4
57.9
1.647 1.04–2.60 0.032